BUSINESS
Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
Sales and operating profit of major Japanese drugs makers in the first half of FY2013 increased from a year before largely due to brisk overseas sales backed by the weak yen. The combined sales and operating profit of 24 Japanese…
To read the full story
Related Article
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
BUSINESS
- Jardiance Triumphs in Six Promotion Channels in April: Intage
May 26, 2026
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
- Datroway Snares US Approval in 1st-Line TNBC: Daiichi Sankyo
May 25, 2026
- Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
May 25, 2026
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





